DIAGNOS Announces Voting Results of Annual Meeting of Shareholders
September 20 2019 - 11:18AM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK)
(OTCQB:DGNOF) a leader in early detection of critical health issues
through the use of its FLAIRE platform based on Artificial
Intelligence (AI), announces the voting results of its annual and
special meeting of shareholders held earlier today.
Election of directors
Mr. Georges Hébert, Mr. André Larente, Dr. Reid
Maclellan, Dr. Jean-François Yale and Mr. François Côté were
elected as directors of the Corporation to hold office until the
closing of the next annual meeting of the shareholders, subject to
the By-laws of the Corporation.
Appointment of auditor
Raymond Chabot Grant Thornton was re-appointed
as auditor of the Corporation for the ensuing year.
Amendment to the stock option
plan
The disinterested shareholders of the
Corporation approved a special resolution pursuant to which the
maximum number of common shares of the Corporation that may be
issued under the stock option plan be set at 6,000,000,
representing an increase of 4,000,000 common shares.
The amendment to the Corporation’s stock option
plan remains subject to the TSX Venture acceptance.
About DIAGNOSDIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of its Artificial Intelligence (“AI”)
tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. Marc-André Massue, CFO and Corporate
SecretaryDIAGNOS IncTel: 450-678-8882 ext. 235
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Diagnos (TSXV:ADK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Sep 2023 to Sep 2024